Pharmacovigilance Market Research Report - Forecast till 2027

Pharmacovigilance Market Research Report: By Clinical Trial Phase (Phase IV, Phase III, Phase II, Phase I, Pre-clinical), By Service Provider (In-house, Contract Outsourcing), By Type (Spontaneous Reporting, Cohort Event Monitoring, Intensified ADR Reporting, EHR Mining) and By End-User (Hospitals, Research Organizations, Pharmaceutical Companies) – Forecast to 2027

ID: MRFR/HC/6979-HCR | February, 2021 | Region : Global

Pharmacovigilance Market Forecast


Pharmacovigilance Market is expected to cross USD 10,881.03 Million by 2025 at a CAGR of 14.1%.


The increasing prevalence of chronic conditions is expected to drive the growth of the pharmacovigilance market. Cancer is the second-leading cause of death worldwide and accounted for nearly 9.6 million deaths in 2018, which increased from 8.9 million deaths in 2016. Out of all the cancers, lung cancer, stomach cancer, colorectal cancer, liver cancer, and breast cancer have the highest mortality rate.


The most common causes of cancer death across the world are cancers of lung, stomach, colorectal, liver, and breast. Considering The increasing year 1995, out of 52 million fatalities, more than 17 million deaths were due to infectious diseases. Moreover, in the year 2016, three contagious diseases were ranked in the top ten causes of death worldwide, which were lower respiratory infections (3.0 million deaths), diarrheal diseases (1.4 million deaths), and tuberculosis (1.3 million deaths).


Pharmacovigilance Market Synopsis


Pharmacovigilance is a relatively new discipline in the pharmaceutical industry. It supports the safe and appropriate use of drugs by identifying risk factors for the development of adverse drug reactions (ADRs), promoting the detection of previously unknown ADRs and their interactions with known ADRs. The increasing incidence of lifestyle diseases, such as hypertension, cardiac disorders, and others, is strongly motivating market players to introduce new efficient drugs in the pharmacovigilance market.


Pharmacovigilance Market Influencers


An increasing number of fatalities due to ADRs is actively facilitating the growth of the pharmacovigilance market. In 2018, 5% of hospital admissions in Europe were due to ADRs, and they account for the fifth most common cause of death in a hospital setting.


Pharmacovigilance Market Drivers




  • Increasing adoption of outsourcing services




  • Growing technological advancements: On May 16, 2019, Accenture launched INTIENT to improve the continuity and flow of data across life sciences enterprises, supporting the delivery of ground-breaking treatments for patients.




  • Growing prevalence of chronic conditions




  • Rising expenditure on oncology medicine and research: Cancer research is receiving attention across the globe. There is a continuous demand for cancer drugs, thus becoming the need of the hour and research activities are in full swing in the US and Europe. According to the IMS Institute for Healthcare Informatics, the global spending on oncology medicines was USD 107 billion in 2015 and is expected to rise to nearly 150 billion by 2020.




  • High spending by the pharmaceutical industry




  • Growing drug consumption and drug development rates




  • Rising cases of adverse drug reactions (ADRs) and medication errors




  • Patent expiration of branded drugs and an increasing number of new drug developments




Pharmacovigilance Market Restraints



  • The shortage of skilled healthcare professionals

  • High costs of maintaining compliance levels


Pharmacovigilance Market Segmentation


By Clinical Trial Phase




  • Phase IV: Phase IV dominated the pharmacovigilance market as adverse drug reactions are majorly detected in this phase




  • Phase III: This phase is expected to witness the fastest growth




  • Phase II: This phase majorly aims to find out if the new treatment works well enough to be tested in a more extensive phase 3 trial




  • Phase I: This phase aims to find the best dose of a new drug with the fewest side effects. The drug is tested in a small group of 15 to 30 patients




  • Pre-clinical: In these trials, a minimal dose of medicine is administered to about 10 to 15 people




By Service Provider




  • In-house: Major benefits offered by in-house manufacturing is having control over the complete process. It has the potential to quickly advance between design, engineering, product development, and production




  • Contract Outsourcing: Contract outsourcing dominated the global pharmacovigilance market and expected to witness the fastest growth. Contract manufacturing serves multiple customers and thus can acquire raw materials at reduced costs, benefiting from the economies of scale. For instance, China is a prime example of gains made from the economy of scale in active pharmaceutical ingredient manufacturing. A long contract manufacturing relationship between the contract manufacturer and the client company ensures the contract manufacturer has a steady flow of business.




By Type




  • Spontaneous Reporting: Held the largest market share in 2018. Spontaneous reporting is a passive approach to pharmacovigilance as it entirely relies on the motivation of individuals to report suspected ADRs to a local or national pharmacovigilance center.




  • Cohort Event Monitoring: This is the fastest-growing segment. It is used to monitor adverse events in patients who receive a particular medication or treatment regimen and to assess causality




  • Intensified ADR Reporting: The main objective of intensified ADR reporting is to enhance ADR reporting of specific medicines in the early post-marketing phase




  • Targeted Spontaneous Reporting: The targeted spontaneous reporting is done to estimate the incidence of a known ADR to a specific drug among a particular group




  • EHR Mining: This method of pharmacovigilance uses existing records to enhance pharmacovigilance




By End-User




  • Hospitals: This segment holds the largest share owing to the increase in the number of hospital admissions due to ADRs




  • Research Organizations: It is the fastest-growing segment as increasing research funding to the research organization to develop effective drugs is expected to support the growth of the pharmacovigilance market during the assessment period




  • Pharmaceutical Companies: With an increasing demand for effective treatment, pharmaceutical companies are coming up with new products which is expected to boost the pharmacovigilance market




By Region




  • Americas: The largest regional market. The presence of major market players is strongly expanding the US pharmacovigilance market. ArisGlobal is one of the leading players that offers innovative pharmacovigilance software and a drug safety platform to transcend all traditional safety data management and reporting processes.




  • Europe: Europe has some of the best healthcare services in the world. Rising healthcare expenditure is one of the key drivers in the Europe pharmacovigilance market. The European Commission (EC) reported that in 2017, the total government expenditure in the European Union (EU) accounted for 45.8% of the gross domestic product (GDP), and government expenditure on health as a proportion of GDP was 7.0%.




  • Asia-Pacific: The fastest-growing regional market for pharmacovigilance, Asia-Pacific, has the world’s largest population and fast-developing healthcare industry. In addition, Asian countries such as China and India continue to draw a significant amount of outsourcing work from developed countries owing to factors such as large-scale manufacturing capacities, low labor costs, low raw material costs, and low manufacturing cost. These factors are projected to drive the growth of the pharmacovigilance market in the region.




  • Middle East & Africa: The Middle East & Africa has been primarily bifurcated into two regions—the Middle East and Africa. The presence of favorable government initiatives and recent healthcare reforms and developing healthcare infrastructure in the Middle East is expected to augment the pharmacovigilance market growth over the forecast period.




Pharmacovigilance Market Key Players



  • Accenture (Ireland)

  • ArisGlobal (US)

  • BioClinica (US)

  • Capgemini (France)

  • Clinquest Group BV (Netherlands)

  • Cognizant (US)

  • IBM Corporation (US)

  • ICON plc. (Ireland)

  • IMEDGlobal (US)

  • ITClinical (Portugal)

  • Laboratory Corporation of America Holdings (US)

  • PAREXEL International Corporation (US)

  • TAKE Solutions Ltd (India)

  • United BioSource Corporation (US)

  • Wipro Ltd (India)

Table of Contents

1. REPORT PROLOGUE

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis

6. GLOBAL PHARMACOVIGILANCE MARKET, BY CLINICAL TRIAL PHASE

6.1. Overview

6.2. Pre-Clinical

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Phase I

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4. Phase II

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5. Phase III

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.6. Phase IV

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7. GLOBAL PHARMACOVIGILANCE MARKET, BY SERVICE PROVIDER

7.1. Overview

7.2. In-House

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Contract Outsourcing

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL PHARMACOVIGILANCE MARKET, BY TYPE

8.1. Overview

8.2. Spontaneous Reporting

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3. Intensified ADR Reporting

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4. Targeted Spontaneous Reporting

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.5. Cohort Event Monitoring

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.6. EHR Mining

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9. GLOBAL PHARMACOVIGILANCE MARKET, BY END USER

9.1. Overview

9.2. Hospitals

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.3. Research Organizations

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.4. Pharmaceutical Companies

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9.5. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

10. GLOBAL PHARMACOVIGILANCE MARKET, BY REGION

10.1. Overview

10.2. Americas

10.2.1. North America

10.2.1.1. US

10.2.1.2. Canada

10.2.2. Latin America

10.3. Europe

10.3.1. Western Europe

10.3.1.1. Germany

10.3.1.2. France

10.3.1.3. Italy

10.3.1.4. Spain

10.3.1.5. UK

10.3.1.6. Rest of Western Europe

10.3.2. Eastern Europe

10.4. Asia-Pacific

10.4.1. Japan

10.4.2. China

10.4.3. India

10.4.4. Australia

10.4.5. South Korea

10.4.6. Rest of Asia-Pacific

10.5. Middle East & Africa

10.5.1. Middle East

10.5.2. Africa

11. COMPANY LANDSCAPE

11.1.1. Overview

11.1.2. Competitive Analysis

12. COMPANY PROFILES

12.1. Accenture

12.1.1. Company Overview

12.1.2. Product Type Overview

12.1.3. Financial Overview

12.1.4. Key Developments

12.1.5. SWOT Analysis

12.1.6. Key Strategies

12.2. ArisGlobal

12.2.1. Company Overview

12.2.2. Product Type Overview

12.2.3. Financial Overview

12.2.4. Key Developments

12.2.5. SWOT Analysis

12.2.6. Key Strategies

12.3. BioClinica

12.3.1. Company Overview

12.3.2. Product Type Overview

12.3.3. Financial Overview

12.3.4. Key Developments

12.3.5. SWOT Analysis

12.3.6. Key Strategies

12.4. Capgemini

12.4.1. Company Overview

12.4.2. Product Type Overview

12.4.3. Financial Overview

12.4.4. Key Developments

12.4.5. SWOT Analysis

12.4.6. Key Strategies

12.5. Clinquest Group BV

12.5.1. Company Overview

12.5.2. Product Type Overview

12.5.3. Financial Overview

12.5.4. Key Developments

12.5.5. SWOT Analysis

12.5.6. Key Strategies

12.6. Cognizant

12.6.1. Company Overview

12.6.2. Product Type Overview

12.6.3. Financial Overview

12.6.4. Key Developments

12.6.5. SWOT Analysis

12.6.6. Key Strategies

12.7. Foresight Group International AG

12.7.1. Company Overview

12.7.2. Product Type Overview

12.7.3. Financial Overview

12.7.4. Key Developments

12.7.5. SWOT Analysis

12.7.6. Key Strategies

12.8. IBM Corporation

12.8.1. Company Overview

12.8.2. Product Type Overview

12.8.3. Financial Overview

12.8.4. Key Developments

12.8.5. SWOT Analysis

12.8.6. Key Strategies

12.9. ICON PLC

12.9.1. Company Overview

12.9.2. Product Type Overview

12.9.3. Financial Overview

12.9.4. Key Developments

12.9.5. SWOT Analysis

12.9.6. Key Strategies

12.10. IMEDGlobal

12.10.1. Company Overview

12.10.2. Product Type Overview

12.10.3. Financial Overview

12.10.4. Key Developments

12.10.5. SWOT Analysis

12.10.6. Key Strategies

12.11. ITClinical

12.11.1. Company Overview

12.11.2. Product Type Overview

12.11.3. Financial Overview

12.11.4. Key Developments

12.11.5. SWOT Analysis

12.11.6. Key Strategies

12.12. Laboratory Corporation of America Holdings

12.12.1. Company Overview

12.12.2. Product Type Overview

12.12.3. Financial Overview

12.12.4. Key Developments

12.12.5. SWOT Analysis

12.12.6. Key Strategies

12.13. PAREXEL International Corporation

12.13.1. Company Overview

12.13.2. Product Type Overview

12.13.3. Financial Overview

12.13.4. Key Developments

12.13.5. SWOT Analysis

12.13.6. Key Strategies

12.14. TAKE Solutions Ltd

12.14.1. Company Overview

12.14.2. Product Type Overview

12.14.3. Financial Overview

12.14.4. Key Developments

12.14.5. SWOT Analysis

12.14.6. Key Strategies

12.15. United BioSource Corporation

12.15.1. Company Overview

12.15.2. Product Type Overview

12.15.3. Financial Overview

12.15.4. Key Developments

12.15.5. SWOT Analysis

12.15.6. Key Strategies

12.16. Wipro Ltd

12.16.1. Company Overview

12.16.2. Product Type Overview

12.16.3. Financial Overview

12.16.4. Key Developments

12.16.5. SWOT Analysis

12.16.6. Key Strategies

12.17. Others

13. APPENDIX

13.1. References

13.2. Related Reports


LIST OF TABLES

TABLE 1 GLOBAL PHARMACOVIGILANCE MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL PHARMACOVIGILANCE MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL PHARMACOVIGILANCE MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL PHARMACOVIGILANCE MARKET, BY SERVICE PROVIDER, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL PHARMACOVIGILANCE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 6 GLOBAL PHARMACOVIGILANCE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 7 GLOBAL PHARMACOVIGILANCE MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 8 NORTH AMERICA: PHARMACOVIGILANCE MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)

TABLE 9 NORTH AMERICA: PHARMACOVIGILANCE MARKET, BY SERVICE PROVIDER, 2020-2027 (USD MILLION)

TABLE 10 NORTH AMERICA: PHARMACOVIGILANCE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 11 NORTH AMERICA: PHARMACOVIGILANCE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 12 US: PHARMACOVIGILANCE MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)

TABLE 13 US: PHARMACOVIGILANCE MARKET, BY SERVICE PROVIDER, 2020-2027 (USD MILLION)

TABLE 14 US: PHARMACOVIGILANCE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 15 US: PHARMACOVIGILANCE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 16 CANADA: PHARMACOVIGILANCE MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)

TABLE 17 CANADA: PHARMACOVIGILANCE MARKET, BY SERVICE PROVIDER, 2020-2027 (USD MILLION)

TABLE 18 CANADA: PHARMACOVIGILANCE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 19 CANADA: PHARMACOVIGILANCE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 20 LATIN AMERICA: PHARMACOVIGILANCE MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)

TABLE 21 LATIN AMERICA: PHARMACOVIGILANCE MARKET, BY SERVICE PROVIDER, 2020-2027 (USD MILLION)

TABLE 22 LATIN AMERICA: PHARMACOVIGILANCE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 23 LATIN AMERICA: PHARMACOVIGILANCE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 24 EUROPE: PHARMACOVIGILANCE MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)

TABLE 25 EUROPE: PHARMACOVIGILANCE MARKET, BY SERVICE PROVIDER, 2020-2027 (USD MILLION)

TABLE 26 EUROPE: PHARMACOVIGILANCE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 27 EUROPE: PHARMACOVIGILANCE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 28 WESTERN EUROPE: PHARMACOVIGILANCE MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)

TABLE 29 WESTERN EUROPE: PHARMACOVIGILANCE MARKET, BY SERVICE PROVIDER, 2020-2027 (USD MILLION)

TABLE 30 WESTERN EUROPE: PHARMACOVIGILANCE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 31 WESTERN EUROPE: PHARMACOVIGILANCE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 32 EASTERN EUROPE: PHARMACOVIGILANCE MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)

TABLE 33 EASTERN EUROPE: PHARMACOVIGILANCE MARKET, BY SERVICE PROVIDER, 2020-2027 (USD MILLION)

TABLE 34 EASTERN EUROPE: PHARMACOVIGILANCE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 35 EASTERN EUROPE: PHARMACOVIGILANCE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 36 ASIA-PACIFIC: PHARMACOVIGILANCE MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)

TABLE 37 ASIA-PACIFIC: PHARMACOVIGILANCE MARKET, BY SERVICE PROVIDER, 2020-2027 (USD MILLION)

TABLE 38 ASIA-PACIFIC: PHARMACOVIGILANCE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 39 ASIA-PACIFIC: PHARMACOVIGILANCE MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA: PHARMACOVIGILANCE MARKET, BY CLINICAL TRIAL PHASE, 2020-2027 (USD MILLION)

TABLE 41 MIDDLE EAST & AFRICA: PHARMACOVIGILANCE MARKET, BY SERVICE PROVIDER, 2020-2027 (USD MILLION)

TABLE 42 MIDDLE EAST & AFRICA: PHARMACOVIGILANCE MARKET, BY TYPE, 2020-2027 (USD MILLION)

TABLE 43 MIDDLE EAST & AFRICA: PHARMACOVIGILANCE MARKET, BY END USER, 2020-2027 (USD MILLION)


LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL PHARMACOVIGILANCE MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL PHARMACOVIGILANCE MARKET

FIGURE 4 GLOBAL PHARMACOVIGILANCE MARKET SHARE, BY CLINICAL TRIAL PHASE, 2020 (%)

FIGURE 5 GLOBAL PHARMACOVIGILANCE MARKET SHARE, BY SERVICE PROVIDER, 2020 (%)

FIGURE 6 GLOBAL PHARMACOVIGILANCE MARKET SHARE, BY TYPE, 2020 (%)

FIGURE 7 GLOBAL PHARMACOVIGILANCE MARKET SHARE, BY END USER, 2020 (%)

FIGURE 8 GLOBAL PHARMACOVIGILANCE MARKET SHARE, BY REGION, 2020 (%)

FIGURE 7 AMERICAS: PHARMACOVIGILANCE MARKET SHARE BY REGION, 2020 (%)

FIGURE 9 NORTH AMERICA: PHARMACOVIGILANCE MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 10 EUROPE: PHARMACOVIGILANCE MARKET SHARE, BY REGION, 2020 (%)

FIGURE 11 WESTERN EUROPE: PHARMACOVIGILANCE MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 ASIA-PACIFIC: PHARMACOVIGILANCE MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 13 MIDDLE EAST & AFRICA: PHARMACOVIGILANCE MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 14 GLOBAL PHARMACOVIGILANCE MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 15 ACCENTURE.: KEY FINANCIALS

FIGURE 16 ACCENTURE: SEGMENTAL REVENUE

FIGURE 17 ACCENTURE: REGIONAL REVENUE

FIGURE 18 ARISGLOBAL: KEY FINANCIALS

FIGURE 19 ARISGLOBAL: SEGMENTAL REVENUE

FIGURE 20 ARISGLOBAL: REGIONAL REVENUE

FIGURE 21 BIOCLINICA: KEY FINANCIALS

FIGURE 22 BIOCLINICA: SEGMENTAL REVENUE

FIGURE 23 BIOCLINICA: REGIONAL REVENUE

FIGURE 24 CAPGEMINI: KEY FINANCIALS

FIGURE 25 CAPGEMINI: SEGMENTAL REVENUE

FIGURE 26 CAPGEMINI: REGIONAL REVENUE

FIGURE 27 CLINQUEST GROUP B.V.: KEY FINANCIALS

FIGURE 28 CLINQUEST GROUP B.V.: SEGMENTAL REVENUE

FIGURE 29 CLINQUEST GROUP B.V.: REGIONAL REVENUE

FIGURE 30 COGNIZANT: KEY FINANCIALS

FIGURE 31 COGNIZANT: SEGMENTAL REVENUE

FIGURE 32 COGNIZANT: REGIONAL REVENUE

FIGURE 33 FORESIGHT GROUP INTERNATIONAL AG: KEY FINANCIALS

FIGURE 34 FORESIGHT GROUP INTERNATIONAL AG: SEGMENTAL REVENUE

FIGURE 35 FORESIGHT GROUP INTERNATIONAL AG: REGIONAL REVENUE

FIGURE 36 IBM CORPORATION: KEY FINANCIALS

FIGURE 37 IBM CORPORATION: SEGMENTAL REVENUE

FIGURE 38 IBM CORPORATION: REGIONAL REVENUE

FIGURE 39 ICON PLC: KEY FINANCIALS

FIGURE 40 ICON PLC: SEGMENTAL REVENUE

FIGURE 41 ICON PLC: REGIONAL REVENUE

FIGURE 42 IMEDGLOBAL: KEY FINANCIALS

FIGURE 43 IMEDGLOBAL: SEGMENTAL REVENUE

FIGURE 44 IMEDGLOBAL: REGIONAL REVENUE




This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.

Pharmacovigilance Market